[Development of a myasthenia crisis during interferon treatment for chronic C hepatitis].
If myasthenia gravis is not a usual complication of interferon therapy, several cases have been described with the use of theses molecules in the treatment of hepatitis C, cancer or multiple sclerosis. We report a new case of serious myasthenia gravis during interferon alpha and ribavirin therapy for hepatitis C.
Reffet
Armel
A
Service des maladies digestives et tropicales, Hôpital d'instruction des armées Robert-Picqué, Bordeaux. reffet.m@wanadoo.fr
Oddes
Bernard
B
Terrier
François
F
Chauveau
Eric
E
Casassus-Buihle
Didier
D
Fraudin
Adrien
A
D000368:Aged; D000998:Antiviral Agents / Q000009:adverse effects*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000627:therapeutic use; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016898:Interferon-alpha / Q000009:adverse effects*; D008297:Male; D009157:Myasthenia Gravis / Q000139:chemically induced*; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011729:Pyridostigmine Bromide / Q000627:therapeutic use; D012254:Ribavirin / Q000009:adverse effects
D000998:Antiviral Agents; D002800:Cholinesterase Inhibitors; D005938:Glucocorticoids; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D016898:Interferon-alpha; D012254:Ribavirin; D009173:Mycophenolic Acid; D011729:Pyridostigmine Bromide; D011241:Prednisone